Targeting the chromatin-reader function of LEDGF/p75 for the treatment of Mixed-Lineage-Leukemia (TReaT-MLL) KU Leuven
Targeting the epigenome is gaining momentum in today’s drug discovery. Aberrant transcription due to dysregulation of epigenetic marks is one of the drivers for malignant transformation in many tumors. Mixed lineage leukemia (MLL)-rearranged acute leukemia (MLL-r) represents a genetically distinct subset of leukemia with poor prognosis (15-40 % event-free survival at 48 months). MLL r leukemia specifically originates from rearrangements in the ...